Journals / Çocuk Dergisi / 2017 / Cilt: 17 - Sayı: 4

How Much We Know about the Use of Adrenaline in Anaphylaxis?

Anafilakside Adrenalin Kullanımı: Ne Kadar Biliniyor?

Pages
139–145
Publication Date
2017-10-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Generally, in adult and pediatric patients, administration of adrenaline in anaphylactic reactions is inadequate and AAI is prescribed at low rates for patients at risk of anaphylaxis

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Anaphylaxis is a life-threatening, emergency clinic conditi- on, so it is essential to diagnose and treat anaphylaxis immediately.
📊
Key Findings & Data:Adrenaline is the first choice in the treatment of anaphylaxis; it is the only drug that prevents death and hospitalization.
💡
Conclusion & Impact:Generally, in adult and pediatric patients, administration of adrenaline in anaphylactic reactions is inadequate and AAI is prescribed at low rates for patients at risk of anaphylaxis
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Anahtar telimeler: Anafilaksi · adrenalin oto-enjektör · tedavi

Abstract

Anaphylaxis is a life-threatening, emergency clinic conditi- on, so it is essential to diagnose and treat anaphylaxis immediately. Adrenaline is the first choice in the treatment of anaphylaxis; it is the only drug that prevents death and hospitalization. It is also very important to prevent anaph- ylaxis as much as treatment, since it is not predictable when it will appear. Adrenaline auto-injectors AAI should be prescribed for individuals who have anaphylaxis and are at high risk for anaphylaxis, and they should be infor- med about when and how to use them. Generally, in adult and pediatric patients, administration of adrenaline in anaphylactic reactions is inadequate and AAI is prescribed at low rates for patients at risk of anaphylaxis

Özet

Anafilaksi YAŞAMI tehdit eden acil bir durumdur, hızla tanı konulup tedavisine başlanmalıdır. Anafilaksi tedavi- sinde ilk seçenek adrenalindir; ölüm ve hastaneye yatışı önleyen tek ilaçtır. Anafilaksinin ne zaman ortaya çıkaca- ğı öngörülemediğinden tedavisi kadar önlenmesi de çok önemlidir. Bu nedenle anafilaksi geçiren ve anafilaksi riski yüksek olan bireylere adrenalin oto-enjektörleri AOE reçete edilmeli, hangi durumlarda ve nasıl kulla- nacakları hakkında bilgi verilmelidir. Genel olarak anafi- lakside adrenalin kullanımı, çocuklarda ve erişkinlerde, yetersiz kalmakta, AOE risk altındaki hastalarda düşük oranda reçetelenmektedir

🔖

Cite This Article

SİPAHİ, S., TAMAY, Z. Ü. (2017). How Much We Know about the Use of Adrenaline in Anaphylaxis?. Çocuk Dergisi, Cilt: 17 - Sayı: 4, 139–145. https://ajindex.com/articles/246846

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Sampson hA, munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and manage- ment of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006;47(4):373-80. https://doi.org/10.1016/j.annemergmed.2006.01.018
  2. Rudders SA, Arias SA, Camargo CA Jr. Trends in hospitalizations for food-induced anaphylaxis in US children, 2000-2009. J Allergy Clin Immunol 2014; 134(4):960-2. https://doi.org/10.1016/j.jaci.2014.06.018 Lee S, hess Ep, Lohse C, Gilani W, Chamberlain Am, Campbell RL. Trends, characteristics, and inci- dence of anaphylaxis in 2001-2010: A population- based study. J Allergy Clin Immunol 2017;139(1):182- 188. https://doi.org/10.1016/j.jaci.2016.04.029
  3. Calvani m, Cardinale F, martelli A, muraro A, pucci N, Savino F, et al. Risk factors for severe pedi- atric food anaphylaxis in Italy. Pediatr Allergy Immunol 2011;22(8):813-9. https://doi.org/10.1111/j.1399-3038.2011.01200.x González-pérez A, Aponte Z, Vidaurre CF, Rodríguez LA. Anaphylaxis epidemiology in patients withand patients without asthma: a United Kingdom database review. J Allergy Clin Immunol 2010;125(5): 1098-104. https://doi.org/10.1016/j.jaci.2010.02.009
  4. Nwaru BI, Dhami S, Sheikh A. Idiopathic anaphyla- xis. Curr Treat Options Allergy 2017;4(3):312-9. https://doi.org/10.1007/s40521-017-0136-2
  5. Simons FER, Ardusso LRF, Bilo mB, El- Gamal ym, Ledford DK, Ring J et al. World Allergy Organization guidelines for the assessment and mana- gement of anaphylaxis. J Allergy Clin Immunol 2011;127:587-93. https://doi.org/10.1016/j.jaci.2011.01.038 Westfall TC. Adrenergic agonists and antagonists. In: Chabner BA, Brunton LL, Knollmann BC, editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2006: 215- 268. muraro A, Roberts G, ClarkA, et al. The manage- ment of anaphylaxis in childhood: position paper of the European Academy of Allergology and Clinical Immunology Allergy 2007;62:857-71. Soreide EB. Severe anaphylactic reactions outside hospital: etiology, symptoms and treatment. Acta Anaesthesiol Scand 1988;32:339-42. https://doi.org/10.1111/j.1399-6576.1988.tb02740.x Kaplan Ap. Anaphylaxis. In: Goldman L, Bennett JC, editors. Ceciltextbook of medicine. 21st ed. Philadelphia: WB Saunders; 2000:1450-2.
  6. Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy ClinImmunol 1998;101(1 Pt 1):33-7.